Cargando…

Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe

BACKGROUND AND AIMS: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer; few treatments exist for patients with advanced disease. Once tumors metastasize to distant sites, patients generally receive chemotherapy, but response duration and progression-free survival (PFS) are typically shor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Becker, Jürgen C., Lorenz, Eva, Ugurel, Selma, Eigentler, Thomas K., Kiecker, Felix, Pföhler, Claudia, Kellner, Ivonne, Meier, Friedegund, Kähler, Katharina, Mohr, Peter, Berking, Carola, Haas, Gabriele, Helwig, Christoph, Oksen, Dina, Schadendorf, Dirk, Mahnke, Lisa, Bharmal, Murtuza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668086/ https://www.ncbi.nlm.nih.gov/pubmed/29108353 http://dx.doi.org/10.18632/oncotarget.19218

Ejemplares similares

Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma
por: Bharmal, Murtuza, et al.
Publicado: (2017)

Correction to: Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma
por: Bharmal, Murtuza, et al.
Publicado: (2019)

Living with Merkel Cell Carcinoma (MCC): Development of a Conceptual Model of MCC Based on Patient Experiences
por: Kaufman, Howard L., et al.
Publicado: (2018)

Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma
por: Nghiem, Paul, et al.
Publicado: (2017)

Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US
por: Bharmal, Murtuza, et al.
Publicado: (2019)

Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany
por: Mohr, Peter, et al.
Publicado: (2022)

Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study
por: Stege, H. M., et al.
Publicado: (2021)

Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
por: Lanitis, Tereza, et al.
Publicado: (2019)

Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma
por: Bullement, Ash, et al.
Publicado: (2019)

Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
por: Zaremba, Anne, et al.
Publicado: (2019)

Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients
por: Lodde, Georg, et al.
Publicado: (2021)

COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma
por: Berking, Carola, et al.
Publicado: (2023)

Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma
por: Spassova, Ivelina, et al.
Publicado: (2022)

Update on the psychometric properties and minimal important difference (MID) thresholds of the FACT-M questionnaire for use in treatment-naïve and previously treated patients with metastatic Merkel cell carcinoma
por: Bharmal, Murtuza, et al.
Publicado: (2020)

Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity
por: Koch, Elias A. T., et al.
Publicado: (2022)

Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis
por: Koch, Elias A. T., et al.
Publicado: (2021)

Exploring the Most Visible German Websites on Melanoma Immunotherapy: A Web-Based Analysis
por: Brütting, Julia, et al.
Publicado: (2018)

Quality, Understandability and Reliability of YouTube Videos on Skin Cancer Screening
por: Reinhardt, Lydia, et al.
Publicado: (2023)

Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab
por: Bharmal, Murtuza, et al.
Publicado: (2020)

Serum S100B, Lactate Dehydrogenase and Brain Metastasis Are Prognostic Factors in Patients with Distant Melanoma Metastasis and Systemic Therapy
por: Weide, Benjamin, et al.
Publicado: (2013)

Merkel cell carcinoma-derived exosome-shuttle miR-375 induces fibroblast polarization by inhibition of RBPJ and p53
por: Fan, Kaiji, et al.
Publicado: (2020)

Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
por: Zimmer, Lisa, et al.
Publicado: (2015)

Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study
por: Bhatia, Shailender, et al.
Publicado: (2022)

Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies
por: Utikal, Jochen, et al.
Publicado: (2007)

Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial
por: Lambert, Jérémy, et al.
Publicado: (2020)

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
por: Glutsch, Valerie, et al.
Publicado: (2021)

Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg Study
por: Stege, Henner, et al.
Publicado: (2021)

How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical trial
por: Bharmal, Murtuza, et al.
Publicado: (2018)

Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
por: Heppt, Markus V., et al.
Publicado: (2019)

Assessment of the Quality, Understandability, and Reliability of YouTube Videos as a Source of Information on Basal Cell Carcinoma: Web-Based Analysis
por: Steeb, Theresa, et al.
Publicado: (2022)

One Website to Gather them All: Usability Testing of the New German SKin Cancer INFOrmation (SKINFO) Website—A Mixed-methods Approach
por: Steeb, Theresa, et al.
Publicado: (2022)

Successful immunotherapy and irradiation in a HIV-positive patient with metastatic Merkel cell carcinoma
por: Linge, Annett, et al.
Publicado: (2018)

Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG
por: Glutsch, Valerie, et al.
Publicado: (2022)

Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis
por: Zaremba, Anne, et al.
Publicado: (2021)

Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations
por: Cosgarea, Ioana, et al.
Publicado: (2017)

Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
por: Haist, Maximilian, et al.
Publicado: (2023)

Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma
por: Ritter, Cathrin, et al.
Publicado: (2017)

Patterns of distant metastases in 215 Merkel cell carcinoma patients: Implications for prognosis and surveillance
por: Lewis, Christopher W., et al.
Publicado: (2019)

Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
por: Placke, Jan-Malte, et al.
Publicado: (2021)

Clinical determinants of long-term survival in metastatic uveal melanoma
por: Koch, Elias A. T., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_17ka2749rbkverenddk1hcb3n5